Key facts
- LongBio Pharma listed on the Hong Kong Stock Exchange on June 5, 2026.
- The company develops innovative drugs for allergic and autoimmune diseases.
- LongBio Pharma is a portfolio company of Qiming Venture Partners.
- This is the seventh IPO for LongBio Pharma.
LongBio Pharma, a prominent Chinese company specializing in the development of innovative drugs for allergic and autoimmune diseases, successfully listed on the Hong Kong Stock Exchange on June 5, 2026, according to Beijing time. This significant event represents the seventh initial public offering (IPO) for the company. LongBio Pharma is recognized as a portfolio company of Qiming Venture Partners, a notable venture capital firm.